The regulatory risks of AI in medical translation: Precision vs efficiency in the EU MDR era

What are the risks of AI in medical translation? The primary risks include terminology "hallucinations" that compromise patient safety, a lack of ISO 17100 compliance, and the absence of a defensible audit trail. In regulated Life Sciences, uncontrolled AI use can lead to regulatory rejection under EU MDR standards and significant legal liability for manufacturers.

What are the key risks of AI in medical translation?

• Terminology hallucinations: Probabilistic language errors that distort essential details such as dosages or contraindications.
• Lack of ISO 17100 compliance: Absence of the mandatory dual-human revision process.
• Absence of audit trail: Inability to trace linguistic decisions for regulatory audits.
• Regulatory non-conformity: Failure to meet EU MDR 2017/745 language and labelling requirements.
• Patient safety exposure: Increased risk of severe or even catastrophic errors in essential documents such as Informed Consent Forms (ICFs) or Instructions For Use (IFUs).
  

Introduction

Artificial intelligence is rapidly reshaping how organisations approach multilingual documentation. In Life Sciences, where clinical timelines are compressed and regulatory expectations continue to expand, AI in medical translation can appear to offer a compelling solution: faster turnaround times, lower costs, and scalable output.

However, in regulated industries governed by the EU Medical Device Regulation (MDR) and stringent quality standards such as ISO 17100, speed alone is not a competitive advantage. Precision, traceability, and accountability remain non-negotiable. When patient safety and regulatory approval are at stake, the risks associated with uncontrolled AI use must be carefully evaluated. This article explores where AI can support medical translation workflows—and where it introduces severe regulatory exposure.

The allure of speed: Why AI in medical translation appeals to CROs

The pharmaceutical and biotech sectors are currently navigating a "perfect storm" of increased data volume and compressed timelines. Generative AI and Large Language Models (LLMs) offer unprecedented scalability, tempting Contract Research Organisations (CROs) to automate the translation of vast technical dossiers.

While the promise of raw throughput is undeniable, the medical field operates on a zero-error threshold. Efficiency must never be confused with effectiveness. In practice, many AI models are probabilistic—they guess the next word based on patterns. In a regulatory dossier, guessing is not an option.

Why AI in medical translation fails ISO 17100 and MDR compliance requirements

The core challenge with raw AI output is the lack of accountability. Under a professional ISO 17100-certified translation process, human revision is not a "quality check"; it is a mandatory legal safeguard to ensure technical accuracy.

AI models lack the cognitive ability to perform linguistic validation—a critical step in ensuring clinical outcomes are culturally appropriate. A simple example of what this might lead to: a manufacturer using unedited AI for an IFU might find that "lead" (the metal) was translated as "lead" (to guide), potentially causing a device failure. The European Medicines Agency (EMA) explicitly warns that AI requires "close human supervision" to mitigate risks.

Terminology hazards: AI hallucinations in medical device translation

AI hallucinations pose the most significant barrier to safe AI adoption in medical terminology translations. Because Large Language Models do not understand clinical science, they can introduce several high-risk errors:

1. Terminology drift: Subtle shifts in meaning that can change the interpretation of dosages, procedures or device functions.
2. Context collapse: Failure to distinguish between similar terms used differently across medical specialties.
3. False cognates: Misinterpretation of terms that appear linguistically similar but carry different regulatory or clinical implications.

In a regulatory environment where precision is mandatory, even a single hallucinated term in a clinical protocol can lead to the immediate suspension of a clinical trial by national authorities.

EU MDR language requirements: Precision as a legal obligation

Compliance with MDR language requirements is a legal prerequisite for market access in Europe. According to EU MDR 2017/745, all IFUs and labelling must be provided in the official language of the Member State where the device is marketed.

In the Netherlands, the IGJ (Health and Youth Care Inspectorate) strictly enforces that safety information is accessible. If an AI-driven translation fails to convey a safety warning with absolute precision, the manufacturer faces product recalls across the European Union.

MTPE vs 100% human translation: A risk-based framework

Machine Translation Post-Editing (MTPE) is effective for low-risk internal documents. However, high-risk regulatory translation services for SmPCs or surgical manuals demand 100% human expertise.

The MediLingua approach: Controlled technology, controlled risk

MediLingua differentiates itself from generic, AI-first providers by maintaining a strictly scientifically grounded and compliance-literate methodology. Our process is defined by:

• Human-led validation: Every technical and/or medical document is reviewed by native-speaking medical subject-matter experts. This ensures that terminology, context, and risk‑related nuances are interpreted correctly.
• Terminology governance: We implement rigorous audit trails to ensure terminology remains consistent across all regulatory submissions.
• Documented QA workflow: Our fully transparent quality assurance process meets the highest medical device translation services standards.

When patient safety is on the line, precision must prevail

AI will continue to play a role in the evolution of medical translation. Ignoring technological advancement is neither realistic nor strategic.

However, in regulated Life Sciences environments, the primary question is not how fast documentation can be produced—but whether it can withstand regulatory scrutiny and protect patient safety.

In this context, clinical precision must take precedence over cost-cutting or operational speed, especially when safety-critical information is involved. Before integrating AI into your translation workflow, ask yourself the following questions:

• Is the process compliant with ISO 17100?
• Does it provide a defensible audit trail?
• Have risks been stratified by document type?
• Who is accountable for terminology accuracy?
  

In the MDR era, linguistic precision is not optional, it is a regulatory obligation.

Ensure your translation strategy aligns with regulatory expectations—not just operational speed. Consult our experts today regarding our ISO 17100-certified translation process.

Frequently Asked Questions (FAQ)

1. Is AI translation allowed under EU MDR? The MDR does not explicitly forbid AI, but it holds the manufacturer fully accountable for the accuracy of all languages. Using raw AI without human revision fails the accountability and safety standards required for CE marking.

2. What is the difference between translation according to ISO 17100 and AI translation? ISO 17100 requires a mandatory "four-eye" principle (two qualified humans) to ensure accuracy. AI translation is a probabilistic tool that lacks this dual-human verification and auditability.

3. When is MTPE safe for medical documents? MTPE is generally safe for internal communication or high-volume, low-risk documentation where a qualified human editor performs the post-editing. It is not recommended for patient-facing or physician-facing safety materials.